TAMPA, Fla.--(BUSINESS WIRE)--June 7, 2006--A majority-owned subsidiary of Accentia Biopharmaceuticals Inc. (NASDAQ: ABPI - News), Biovest International Inc. (OTCBB: BVTI - News) delivered a presentation entitled "Idiotype Vaccine Therapy of Follicular Lymphoma in First Remission: Association of t(14;18) and Disease Free Survival in a Phase II Cohort" at the annual meeting of the American Society for Clinical Oncology in Atlanta, GA on June 3, 2006. The presentation was authored by BL Gause, SS Neelapu, CM Cohen, LM Katz, TM Watson, AM Stergiou and LW Kwak, from the National Cancer Institute, MD Anderson Cancer Center and Biovest International. The data, representing follow up analysis of patients with follicular lymphoma treated with BiovaxID(TM) in a phase 2 trial, showed that 9.2 years after treatment 95% of BiovaxID treated patients were still alive and 45% remained disease free.
